Optimizing Anticancer Therapy in Prostate Cancer Guideline
Apr 02, 2018•18 min•Ep. 3
Listen to this episode in Metacast mobile app
Don't just listen to podcasts. Learn from them with transcripts, summaries, and chapters for every episode. Skim, search, and bookmark insights. Learn more
Episode description
An interview with Dr. Michael J. Morris from Memorial Sloan Kettering Cancer Center and Weill Cornell Medicine on the ASCO clinical practice guideline which addresses abiraterone or docetaxel with androgen-deprivation therapy (ADT) for metastatic prostate cancer that has not been treated (or has been minimally treated) with testosterone-lowering agents. Read the full guideline at www.asco.org/genitourinary-cancer-guidelines
For the best experience, listen in Metacast app for iOS or Android